Amneal to Virtually Participate at the 40th Annual J.P. Morgan Healthcare Conference
21 Dezember 2021 - 02:00PM
Business Wire
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today
announced that Chirag Patel, Amneal’s Co-Chief Executive Officer
and President, will present at the 40th Annual J.P. Morgan
Healthcare Conference on January 12, 2022 at 11:15 AM Eastern Time.
A live webcast of the presentation and subsequent Q&A session
will be accessible through the Investor Relations section of the
Company's website at https://investors.amneal.com. A replay of the
webcast will be posted shortly after the call and will be available
for 30 days following the event.
About Amneal
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in
Bridgewater, NJ, is a fully-integrated essential medicines company.
We make healthy possible through the development, manufacturing,
and distribution of generic and specialty pharmaceuticals,
primarily within the United States. The Company has a diverse
portfolio of approximately 250 products in its Generics business
and is expanding across a broad range of complex products and
therapeutic areas, including injectables and biosimilars. In its
Specialty business, Amneal has a growing portfolio of branded
pharmaceutical products focused primarily on central nervous system
and endocrine disorders, with a pipeline focused on unmet needs.
Through its AvKARE business, the Company is a distributor of
pharmaceuticals and other products for the U.S. federal government,
retail, and institutional markets. For more, please visit
www.amneal.com.
Forward-Looking Statements
Certain statements contained herein, regarding matters that are
not historical facts, may be forward-looking statements (as defined
in the U.S. Private Securities Litigation Reform Act of 1995). Such
forward-looking statements include statements regarding
management’s intentions, plans, beliefs, expectations or forecasts
for the future, including among other things: discussions of future
operations; expected operating results and financial performance;
impact of planned acquisitions and dispositions; the Company’s
strategy for growth; product development; regulatory approvals;
market position and expenditures. Words such as “plans,” “expects,”
“will,” “anticipates,” “estimates” and similar words are intended
to identify estimates and forward-looking statements.
The reader is cautioned not to rely on these forward-looking
statements. These forward-looking statements are based on current
expectations of future events. If the underlying assumptions prove
inaccurate or known or unknown risks or uncertainties materialize,
actual results could vary materially from the expectations and
projections of the Company.
Such risks and uncertainties include, but are not limited to:
the impact of the COVID-19 pandemic; the impact of global economic
conditions; our ability to successfully develop, license, acquire
and commercialize new products on a timely basis; our ability to
obtain exclusive marketing rights for our products; the competition
we face in the pharmaceutical industry from brand and generic drug
product companies, and the impact of that competition on our
ability to set prices; our ability to manage our growth through
acquisitions and otherwise; our dependence on the sales of a
limited number of products for a substantial portion of our total
revenues; the risk of product liability and other claims against us
by consumers and other third parties; risks related to changes in
the regulatory environment, including U.S. federal and state laws
related to healthcare fraud abuse and health information privacy
and security and changes in such laws; changes to FDA product
approval requirements; risks related to federal regulation of
arrangements between manufacturers of branded and generic products;
the impact of healthcare reform and changes in coverage and
reimbursement levels by governmental authorities and other
third-party payers; the continuing trend of consolidation of
certain customer groups; our reliance on certain licenses to
proprietary technologies from time to time; our dependence on
third-party suppliers and distributors for raw materials for our
products and certain finished goods; our dependence on third-party
agreements for a portion of our product offerings; our ability to
identify, make and integrate acquisitions or investments in
complementary businesses and products on advantageous terms; legal,
regulatory and legislative efforts by our brand competitors to
deter competition from our generic alternatives; the significant
amount of resources we expend on research and development; our
substantial amount of indebtedness and our ability to generate
sufficient cash to service our indebtedness in the future, and the
impact of interest rate fluctuations on such indebtedness; the
impact of severe weather; and the high concentration of ownership
of our Class A Common Stock and the fact that we are controlled by
the Amneal Group. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties that
are described from time to time in the Company’s filings with the
Securities and Exchange Commission, including under Item 1A, “Risk
Factors” in the Company’s most recent Annual Report on Form 10-K
and in its subsequent reports on Forms 10-Q and 8-K. Investors are
cautioned not to place undue reliance on any such forward-looking
statements, which speak only as of the date they are made.
Forward-looking statements included herein speak only as of the
date hereof and we undertake no obligation to revise or update such
statements to reflect the occurrence of events or circumstances
after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211221005081/en/
Anthony DiMeo Senior Director, Investor Relations
anthony.dimeo@amneal.com
Amneal Pharmaceuticals (NYSE:AMRX)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Amneal Pharmaceuticals (NYSE:AMRX)
Historical Stock Chart
Von Mär 2023 bis Mär 2024